Clincosm LogoSign in Get a demo

Characterization of Endocarditis to Streptococci and Impact of the CMI on the Future of the Patients

Sponsor
Groupe Hospitalier Paris Saint Joseph (Other)
Overall Status
Completed
CT.gov ID
NCT03306225
Collaborator
(none)
414
Enrollment
1
Location
41.8
Actual Duration (Months)
9.9
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The infectious endocarditis is a grave infection the incidence of which is at present esteemed at 30-100 episodes by million inhabitants a year.

This infection is marked with a heavy morbi-mortality.Preliminary studies seem to show an abnormally high death rate at the patients presenting an infectious endocarditis to streptococci with an inhibitive minimal concentration raised to the amoxicilline. The aim of the study is to describe the epidemiology and the clinical presentations of the patients presenting an endocarditis to streptococci

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    414 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Characterization of Endocarditis to Streptococci and Impact of the CMI on the Future of the Patients
    Actual Study Start Date :
    Jul 8, 2016
    Actual Primary Completion Date :
    Dec 31, 2018
    Actual Study Completion Date :
    Dec 31, 2019

    Outcome Measures

    Primary Outcome Measures

    1. Evaluation of factors associated to the mortality in the patients presenting an endocarditis to streptococci. [an average of one year]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • age > 18 years

    • endocartitis with steptococci with Duke's criteria

    Exclusion Criteria:

    • age < 18 years

    • suspiscious endocarditis without Duke's criteria

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Groupe Hospitalier Paris Saint Joseph Paris Ile-de-France France 75014

    Sponsors and Collaborators

    • Groupe Hospitalier Paris Saint Joseph

    Investigators

    • Principal Investigator: PILMIS P Benoit, MD, Groupe Hospitalier Paris Saint Joseph

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Groupe Hospitalier Paris Saint Joseph
    ClinicalTrials.gov Identifier:
    NCT03306225
    Other Study ID Numbers:
    • ENDOSTREPTO
    First Posted:
    Oct 10, 2017
    Last Update Posted:
    Feb 5, 2020
    Last Verified:
    Jan 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Endocarditis, Bacterial
    Endocarditis

    Study Results

    No Results Posted as of Feb 5, 2020